DOI:
10.1055/s-00000002
Aktuelle Dermatologie
LinksClose Window
References
Verstovsek S.
Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Postgrad Med 2013;
125: 128-135
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.